Novavax: Is This Time Different?

1/12/18

Novavax (NVAX) surged over $2 on positive indications of a drug in a pivotal Phase 3 trial. The small biotech has been in this position before and investors came away with tears.

Source: Novavax

Back Again

The impetus for the big 60% rally on Wednesday was the presentation at the JPMorgan Healthcare Conference that showed positive indications for the Prepare vaccine. The RSV F vaccine in newborns by immunizing mothers (IVM) had already expected strong results by the end of 2017, but the biotech extended the trial and continues to extend the interim data readout.

The positive analysis comes after Novavax had originally expected the Resolve vaccine for RSV F in older adults to provide the key drug for the RSV franchise. Those pivotal Phase 3 results failed to meet expectations and crushed the stock back in 2016.

READ FULL ARTICLE HERE

It's on us. Share your news here.

Submit your stories and articles to citybizlist today.

Baltimore Business Spotlight

Feature Your Business Here

Connect with these Baltimore Professionals on LinkedIn

  • Edwin Warfield

    Editor in Chief, Warfield Digital

    Connect
  • Jean Halle

    Independent Consultant

    Connect
  • Larry Lichtenauer

    President of Lawrence Howard & Associates

    Connect
  • Newt Fowler

    Partner at Womble Carlyle, LLP

    Connect
  • David Crowley

    Owner at Develop DC

    Connect
  • Carolyn Stinson

    Stinson Marketing Group

    Connect